SCHEMBL852699

SCHEMBL852699

COC(=O)c1cc2ccccc2cc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
HSD11B1 P28845 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
EPAS1 Q99814 1/20 0.41
SDHB P21912 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31150577 1.00 KDM4E (0.48) KDM4EALDH1A1HPGDHSD11B1NPSR1
SCHEMBL18952971 0.91 HSD11B1 (0.41) KDM4EALDH1A1HPGDHSD11B1L3MBTL1
SCHEMBL16513114 0.89 HSD11B1 (0.50) KDM4EALDH1A1HPGDHSD11B1SLC6A2
SCHEMBL18952972 0.87 KDM4E (0.42) KDM4EALDH1A1HPGDHSD11B1NPSR1
SCHEMBL17877014 0.87 HSD11B1 (0.43) KDM4EALDH1A1HPGDHSD11B1NPSR1
SCHEMBL14063330 0.87 HSD11B1 (0.46) KDM4EALDH1A1HSD11B1L3MBTL1EPAS1
SCHEMBL7214605 0.87 KDM4E (0.49) KDM4EALDH1A1HPGDHSD11B1NPSR1
SCHEMBL7658363 0.86 KDM4E (0.43) KDM4EALDH1A1HPGDHSD11B1LMNA
SCHEMBL17913590 0.86 EPAS1 (0.45) KDM4EHSD11B1EPAS1KMT2AMEN1
SCHEMBL11955735 0.85 KDM4E (0.47) KDM4EALDH1A1HPGDHSD11B1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618722-B2 Compound, composition, organic electroluminescent element, and electronic appliance IDEMITSU KOSAN CO., LTD. (JP) 2023-04-04 US disclosed
US-10396288-B2 Organic electroluminescent element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2019-08-27 US disclosed
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE DEUTSCHLAND (DE) 2018-12-06 US disclosed
US-9879033-B2 Modulators of 5-HT receptors and methods of use thereof AbbVie Deutschland GmbH & Co. KG (DE) 2018-01-30 US disclosed
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 EP disclosed
US-20160181543-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20160181543-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC. 2016-04-07 US disclosed
US-9187483-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2015-11-17 US disclosed
EP-2641907-B1 Preparation of modulators of 5-HT receptors ABBVIE INC (US) 2015-01-28 EP disclosed
WO-2010135560-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-11-25 WO disclosed
US-20100298292-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-11-25 US disclosed
US-20100094014-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS MARTINEZ-PEREZ JOSE ANTONIO 2010-04-15 US disclosed
EP-2166003-A1 Excitatory amino acid receptor antagonists Eli Lilly & Company (US) 2010-03-24 EP disclosed
US-7601738-B2 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 2009-10-13 US disclosed
US-7205313-B2 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 2007-04-17 US disclosed
US-20060100237-A1 Excitatory amino acid receptor antagonists ARNOLD MACKLIN B 2006-05-11 US disclosed
US-20040138254-A1 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1368032-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2003024453-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138254-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, GRIN1 KDM4E 3336/4885ALDH1A1 1633/4885HPGD 2300/4885
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C KDM4E 1480/4885ALDH1A1 971/4885HPGD 504/4885
US-20100298292-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C KDM4E 1480/4885ALDH1A1 971/4885HPGD 504/4885
US-20100094014-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS SLC1A2, SLC1A1, GRIN1 KDM4E 3336/4885ALDH1A1 1633/4885HPGD 2300/4885
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C KDM4E 1480/4885ALDH1A1 971/4885HPGD 504/4885
US-11618722-B2 Compound, composition, organic electroluminescent element, and electronic appliance FGF23, SUZ12, RPL24 KDM4E 503/4885ALDH1A1 3606/4885HPGD 3219/4885
US-10396288-B2 Organic electroluminescent element and electronic device RER1, LEF1, ELP1 KDM4E 3266/4885ALDH1A1 787/4885HPGD 4553/4885
US-20160181543-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE RER1, LEF1, RPL18 KDM4E 3259/4885ALDH1A1 804/4885HPGD 4545/4885
US-20060100237-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, GRIN1 KDM4E 3336/4885ALDH1A1 1633/4885HPGD 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.